by Inhaled Antibiotics provide localized drug delivery directly to the site of infection in the lungs without systemic exposure and side effects. These products are easy-to-use, portable inhalation devices for the treatment of various respiratory diseases like cystic fibrosis, bronchiectasis and severe lung infections.
The global Inhaled Antibiotics Market is estimated to be valued at US$ 1,403.3 Mn in 2023 and is expected to exhibit a CAGR of 6.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Key Trends
Increasing prevalence of respiratory diseases.
One of the major drivers of the Inhaled Antibiotics Market is the rising prevalence of various respiratory diseases globally. As per the statistics provided by World Health Organization (WHO), respiratory diseases accounted for one in every six deaths globally in 2019. The prevalence of chronic respiratory diseases like cystic fibrosis and bronchiectasis has been rising significantly. Inhaled antibiotics provide effective treatment for respiratory infections associated with these chronic respiratory diseases. Their localized delivery helps improve patient compliance and clinical outcomes compared to conventional oral or intravenous antibiotic therapy for treatment of lung infections. Thus, the growing burden of respiratory diseases worldwide is expected to propel the demand for inhaled antibiotics over the forecast period.
SWOT Analysis
Strength: Inhaled antibiotics allow direct delivery of drugs to the site of infection in the lungs, bypassing digestive system. This results in higher efficacy with lower systemic side effects.
Weakness: Development of antibiotic resistance to existing inhaled antibiotics. Not all patients can effectively use inhalers for administration.
Opportunity: Large patient pool of cystic fibrosis and various other respiratory infections present market opportunity. Development of novel inhaled antibiotic formulations can further drive the market growth.
Threats: Intense competition from existing intravenous antibiotic therapies. Stringent regulatory approvals for new inhaled antibiotic drugs.
Key Takeaways
The global Inhaled Antibiotics Market Growth is expected to witness high growth over the forecast period of 2023 to 2030. The market size is projected to reach US$ 1,403.3 Mn in 2023 registering a CAGR of 6.7% during the forecast period.
Regional analysis: North American region currently dominates the global inhaled antibiotics market owing to higher adoption and presence of major players. However, Asia Pacific region is expected to witness the fastest growth due to rising incidence of respiratory infections and growing awareness.
Key players: Key players operating in the inhaled antibiotics market are Gilead Sciences, Aradigm, Lupin Ltd., Polyphor, Insmed Incorporated, Pharmaero, Savara Pharmaceuticals, Joincare Pharmaceutical Group, Teva Pharmaceuticals, Altan Pharmaceuticals, Raptor Pharmaceutical Corp., Cipla Limited, Maya Biotech Pvt. Ltd., Medisol Lifescience Pvt. Ltd., Nivon Specialties, Sentiss Pharma Pvt. Ltd., Ultratech India Limited, Midas Care Pharmaceuticals Pvt Ltd., Precept Pharma Ltd., Luckys Pharma, and Pharmaxis Ltd. These players are focusing on developing novel formulations with improved efficacy and reduced resistance.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
